论文部分内容阅读
门静脉高压( PHT)是肝硬化后期的一个重要并发症，其引起的上消化道出血、脾大、腹腔积液、侧支循环形成严重影响患者的生存质量。由于PHT发病机制复杂、肝内和肝外存在诸多矛盾，导致临床上缺乏有效治疗PHT的药物，这也是目前PHT治疗的瓶颈问题之一。因此，深入研究PHT的形成机制，开发安全有效、不良反应少的药物一直是该领域的研究热点。调节血管收缩的RhoA/Rho激酶信号途径异常可能是PHT形成的关键机制之一。该文总结了近年来RhoA/Rho激酶信号途径在PHT发病机制中的研究进展，旨在为开发治疗PHT的药物提供新思路。“,”Portal hypertension is a complication of liver cirrhosis. The upper gastrointestinal bleeding, splenomegaly,ascites and collateral circulation resulted from PHT have very serious affect on the life quality of patients. Since the pathogenesis of PHT is complicated,especially the contradiction between intrahepatic and extrahepatic mechanisms,there are no perfect medicine for PHT,which is also a pivotal problem for PHT treatment. Therefore, studying the mechanism of PHT and developing safe and effective drugs with fewer side effects are the focus of this filed. Many studies have indicated that dysfunction of RhoA/Rho kinase signaling pathway may be one of the key mechanisms of PHT. This paper summarizes recent progress of RhoA/Rho ki-nase signaling pathway in the pathogenesis of PHT,to provide new ideas for drugs development.